MINIMED INC (MMED)
Health Care · Diabetes management devices and digital health · NASDAQ
MiniMed is a diabetes care technology company specializing in automated insulin delivery pumps, continuous glucose monitors, and smart insulin pens for global Type 1 and Type 2 diabetes management.
What MINIMED INC does
MiniMed develops and markets insulin delivery systems, continuous glucose monitoring (CGM) devices, and smart insulin pen systems for the management of Type 1 and Type 2 diabetes. The company's core product portfolio includes automated insulin delivery (AID) systems like the MiniMed 780G and MiniMed Flex pumps, CGM products such as Guardian Connect, Simplera Sync, and Instinct, and smart multiple daily injection systems including the InPen smart insulin pens. MiniMed operates in over 80 countries and competes across a range of diabetes management technologies serving people with diabetes globally.
Themes: ["Automated insulin delivery / AID systems","Continuous glucose monitoring (CGM)","Type 1 diabetes management","Type 2 diabetes management","Connected diabetes devices","Digital health / mobile diabetes apps"]
Fundamentals
- Price$15.05 as of 2026-07-09 close
- Market cap$4.2B as of 2026-07-10
- 1-year return-18.6% as of 2026-07-09 close
- Net margin-10.7% as of 2026-07-10
- Gross margin+54.2% as of 2026-07-10
- ROE-9.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue CAGR (3y)+12.1% SEC XBRL
- Beta0.24 as of 2026-07-10
Key risks (from latest filing)
["Intense competition from established players (Dexcom, Tandem Diabetes Care, Insulet) and emerging competitors in insulin pumps, CGMs, and smart insulin systems, which could erode market share and pricing power","Dependence on reimbursement approval from healthcare insurance providers; regulatory changes in the FDA and other jurisdictions could impact market access and product adoption","Risk of patent expiration on proprietary products leading to generic or reprocessed product competition, and customer delay in purchasing current products if waiting for new product announcements"]
Competitors & peers
- Dexcom, Inc. (DXCM)
- Tandem Diabetes Care, Inc. (TNDM)
- Insulet Corporation (PODD)
- Beta Bionics, Inc.
- Sequel Med Tech, LLC
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.